|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Datamonitor, Aug 2010, Pages: 132
Introduction
The oncology market has witnessed a sizeable shift of focus away from cytotoxic therapies and antihormonal therapies towards the more lucrative targeted therapies and immunotherapies class in the last decade. This class boasts several of the top-selling anticancer brands overall, and has fueled most of the recent rapid growth of the oncology market as a whole.
Scope
-Forecast sales of every marketed cancer targeted therapy and immunotherapy in each of the seven major markets over the period 2009 to 2019
-Analysis and segmentation of the market at various levels including drug class, country, brand and company
-Comprehensive brand profiles and analysis for the key brands, including approval dates, patent expiries and all key events likely to impact sales
-Snapshot of the cancer targeted therapies and immunotherapies market in the rest of the world
Highlights
Between 2010 and 2019, conditions in the oncology market will support relatively high growth rates for the targeted therapies and immunotherapies currently on the market. Combined sales in this class will grow at a CAGR of 6.6 % from $19.5 billion in 2009 to reach $36.8 billion in 2019.
Avastin (bevacizumab; Roche/Chugai) was the leading oncology brand in 2009. Despite a number of setbacks (including failures in Phase III trials in certain new indications) and potential threats, sales of Avastin will continue to grow, driven by further indication expansions and increasing uptake in existing indications and new territories.
With a dominant presence in three of the four highest incidence solid tumors and the highest incidence hematological malignancy, Roche dominates the cancer targeted therapies and immunotherapies market. This will continue through to 2019, driven by the strong performance of the company’s monoclonal antibody franchise.
Reasons to Purchase
-Quantify the performance of each of the marketed cancer targeted therapies and immunotherapies in the seven major markets over the period 2009 to 2019
-Assess the changing key opportunities and threats both for currently marketed and pipeline targeted therapy and immunotherapy brands
-Identify the leading brands in this market over the next 10 years and understand the key factors driving their success
Customers who bought this item also bought
Commercial Insight: Top 20 Cancer Therapy Brands
Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic sales
Drug Delivery in Cancer - Technologies, Markets and Companies
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
Commercial Insight: Antihormonal Cancer Therapies - Leading brands strive to minimize generic sales erosion
Market and Product Forecasts: Top 20 Oncology Therapy Brands - The value of the top 20 decreases as the oncology market fragments
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
Pipeline and Commercial Insight: Allergic Rhinitis - Immunotherapy Growth Surpassed by Generic Erosion
Gastric Cancer Drug Discoveries: What the Future Holds
|
|
|
|
